Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

Domingo Hernández, Teresa Vázquez-Sánchez, Eugenia Sola, Veronica Lopez, Pedro Ruiz-Esteban, Abelardo Caballero, Eduardo Salido, Myriam Leon, Aurelio Rodriguez, Nuria Serra, Consuelo Rodriguez, Carme Facundo, Manel Perello, Irene Silva, Domingo Marrero-Miranda, Ignacio Cidraque, Francesc Moreso, Luis Guirado, Daniel Serón, Armando Torres, Domingo Hernández, Teresa Vázquez-Sánchez, Eugenia Sola, Veronica Lopez, Pedro Ruiz-Esteban, Abelardo Caballero, Eduardo Salido, Myriam Leon, Aurelio Rodriguez, Nuria Serra, Consuelo Rodriguez, Carme Facundo, Manel Perello, Irene Silva, Domingo Marrero-Miranda, Ignacio Cidraque, Francesc Moreso, Luis Guirado, Daniel Serón, Armando Torres

Abstract

Background: Subclinical inflammation, including borderline lesions (BL), is very common (30-40%) after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. Few controlled studies have analyzed the therapeutic benefit of treating these BL on renal function and graft histology. Furthermore, these studies have only used bolus steroids, which may be insufficient to slow the progression of these lesions. Klotho, a transmembrane protein produced mainly in the kidney with antifibrotic properties, plays a crucial role in the senescence-inflammation binomial of kidney tissue. Systemic and local inflammation decrease renal tissue expression and soluble levels of α-klotho. It is therefore important to determine whether treatment of BL prevents a decrease in α-klotho levels, progression of IFTA, and loss of kidney function.

Methods: The TRAINING study will randomize 80 patients with low immunological risk who will receive their first KT. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with polyclonal rabbit antithymocyte globulin (Grafalon®) (6 mg/kg/day) prevents or decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT, as well as to analyze whether treatment of BL with Grafalon® can modify the expression and levels of klotho, as well as the pro-inflammatory cytokines that regulate its expression.

Discussion: This phase IV investigator-driven, randomized, placebo-controlled clinical trial will examine the efficacy and safety of Grafalon® treatment in low-immunological-risk KT patients with early BL.

Trial registration: clinicaltrials.gov : NCT04936282. Registered June 23, 2021, https://ichgcp.net/clinical-trials-registry/NCT04936282?term=NCT04936282&draw=2&rank=1 . Protocol Version 2 of 21 January 2022.

Sponsor: Canary Isles Institute for Health Research Foundation, Canary Isles (FIISC). mgomez@fciisc.org .

Keywords: borderline lesions; kidney transplant; subclinical inflammation; α-klotho, low immunological risk.

Conflict of interest statement

The authors declare no conflict of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Scheme and determinations of the study

References

    1. Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med. 2021;385(8):729–743. doi: 10.1056/NEJMra2014530.
    1. Riella LV, Djamali A, Pascual J. Chronic allograft injury: Mechanisms and potential treatment targets. Transplant Rev (Orlando) 2017;31(1):1–9. doi: 10.1016/j.trre.2016.10.005.
    1. Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, Rush D. Long-term deterioration of kidney allograft function. Am J Transplant. 2005;5(6):1405–1414. doi: 10.1111/j.1600-6143.2005.00853.x.
    1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–2333. doi: 10.1056/NEJMoa020009.
    1. García-Carro C, Dörje C, Åsberg A, Midtvedt K, Scott H, Reinholt FP, Holdaas H, Seron D, Reisæter AV. Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies. Transplantation. 2017;101(6):1410–1415. doi: 10.1097/TP.0000000000001216.
    1. Ortiz F, Gelpi R, Helanterä I, Melilli E, Honkanen E, Bestard O, Grinyo JM, Cruzado JM. Decreased Kidney Graft Survival in Low Immunological Risk Patients Showing Inflammation in Normal Protocol Biopsies. PLoS One. 2016;11(8):e0159717. doi: 10.1371/journal.pone.0159717.
    1. Rush DN, Gibson IW. Subclinical Inflammation in Renal Transplantation. Transplantation. 2019;103(6):e139–e145. doi: 10.1097/TP.0000000000002682.
    1. Nankivell BJ, Agrawal N, Sharma A, Taverniti A, P'Ng CH, Shingde M, Wong G, Chapman JR. The clinical and pathological significance of borderline T cell-mediated rejection. Am J Transplant. 2019;19(5):1452–1463. doi: 10.1111/ajt.15197.
    1. Moreso F, Ibernon M, Gomà M, Carrera M, Fulladosa X, Hueso M, Gil-Vernet S, Cruzado JM, Torras J, Grinyó JM, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant. 2006;6(4):747–752. doi: 10.1111/j.1600-6143.2005.01230.x.
    1. Mehta RB, Tandukar S, Jorgensen D, Randhawa P, Sood P, Puttarajappa C, Zeevi A, Tevar AD, Hariharan S. Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications. Kidney Int. 2020;98(2):436–447. doi: 10.1016/j.kint.2020.03.028.
    1. Hernández D, Alonso-Titos J, Vázquez T, León M, Caballero A, Cobo MA, et al. Clinical Relevance of Corticosteroid Withdrawal on Graft Histological Lesions in Low-Immunological-Risk Kidney Transplant Patients. J Clin Med. 2021;10(9):2005. doi: 10.3390/jcm10092005.
    1. Mehta R, Bhusal S, Randhawa P, Sood P, Cherukuri A, Wu C, Puttarajappa C, Hoffman W, Shah N, Mangiola M, et al. Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol. Am J Transplant. 2018;18(7):1710–1717. doi: 10.1111/ajt.14627.
    1. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20(9):2318–2331. doi: 10.1111/ajt.15898.
    1. Beimler J, Zeier M. Borderline rejection after renal transplantation–to treat or not to treat. Clin Transpl. 2009;23(Suppl 21):19–25. doi: 10.1111/j.1399-0012.2009.01105.x.
    1. Kee TY, Chapman JR, O'Connell PJ, Fung CL, Allen RD, Kable K, Vitalone MJ, Nankivell BJ. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation. 2006;82(1):36–42. doi: 10.1097/01.tp.0000225783.86950.c2.
    1. Park SH, Friedewald JJ. Are borderline changes real rejection? Current viewpoints. Curr Opin Nephrol Hypertens. 2020;29(6):656–662. doi: 10.1097/MNH.0000000000000648.
    1. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81(9):1227–1233. doi: 10.1097/01.tp.0000219817.18049.36.
    1. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967–1977. doi: 10.1056/NEJMoa060068.
    1. Oostenbrink LVE, Jol-van der Zijde CM, Kielsen K, Jansen-Hoogendijk AM, Ifversen M, Müller KG, Lankester AC, van Halteren AGS, Bredius RGM, Schilham MW, et al. Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation. Front Immunol. 2019;10:315. doi: 10.3389/fimmu.2019.00315.
    1. Shimony O, Nagler A, Gellman YN, Refaeli E, Rosenblum N, Eshkar-Sebban L, Yerushalmi R, Shimoni A, Lytton SD, Stanevsky A, et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J Clin Immunol. 2012;32(1):173–188. doi: 10.1007/s10875-011-9599-2.
    1. Izquierdo MC, Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Ruiz-Andres O, Poveda J, Moreno JA, Egido J, Ortiz A. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant. 2012;27(Suppl 4):iv6–i10. doi: 10.1093/ndt/gfs426.
    1. Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, et al. Circulating α-klotho levels in CKD and relationship to progression. Am J Kidney Dis. 2013;61(6):899–909. doi: 10.1053/j.ajkd.2013.01.024.
    1. Zhou L, Mo H, Miao J, Zhou D, Tan RJ, Hou FF, Liu Y. Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin System. Am J Pathol. 2015;185(12):3211–3223. doi: 10.1016/j.ajpath.2015.08.004.
    1. Otani-Takei N, Masuda T, Akimoto T, Honma S, Watanabe Y, Shiizaki K, Miki T, Kusano E, Asano Y, Kuro OM, et al. Association between Serum Soluble Klotho Levels and Mortality in Chronic Hemodialysis Patients. Int J Endocrinol. 2015;2015:406269. doi: 10.1155/2015/406269.
    1. Ruiz-Andres O, Sanchez-Niño MD, Moreno JA, Ruiz-Ortega M, Ramos AM, Sanz AB, Ortiz A. Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. Am J Physiol Renal Physiol. 2016;311(6):F1329–f1340. doi: 10.1152/ajprenal.00487.2016.
    1. Moreno JA, Izquierdo MC, Sanchez-Niño MD, Suárez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol. 2011;22(7):1315–1325. doi: 10.1681/ASN.2010101073.
    1. Nankivell BJ, P'Ng CH, Chapman JR. Does tubulitis without interstitial inflammation represent borderline acute T cell mediated rejection? Am J Transplant. 2019;19(1):132–144. doi: 10.1111/ajt.14888.
    1. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol. 2008;3(Suppl 2):S101–S116. doi: 10.2215/CJN.03510807.
    1. Dobbels F, Berben L, De Geest S, Drent G, Lennerling A, Whittaker C, Kugler C. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation. 2010;90(2):205–219. doi: 10.1097/TP.0b013e3181e346cd.
    1. Xu C, Chang A, Hack BK, Eadon MT, Alper SL, Cunningham PN. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis. Kidney Int. 2014;85(1):72–81. doi: 10.1038/ki.2013.286.
    1. Sharif MN, Campanholle G, Nagiec EE, Wang J, Syed J, O'Neil SP, Zhan Y, Brenneman K, Homer B, Neubert H, et al. Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease. PLoS One. 2016;11(5):e0155368. doi: 10.1371/journal.pone.0155368.
    1. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol. 2010;21(11):1987–1997. doi: 10.1681/ASN.2010010049.
    1. Kurtkoti J, Sakhuja V, Sud K, Minz M, Nada R, Kohli HS, Gupta KL, Joshi K, Jha V. The utility of 1- and 3-month protocol biopsies on renal allograft function: a randomized controlled study. Am J Transplant. 2008;8(2):317–323. doi: 10.1111/j.1600-6143.2007.02049.x.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다